NOVELVI®
Noninvasive Prenatal Test (NIPT)
Novelvi® Panels
Novelvi® can be performed as soon as 10 weeks into pregnancy to evaluate the health of the developing fetus. The test screens for chromosomal abnormalities (aneuploidy) which can be associated with severe syndromes. Our Novelvi® panels use the latest sequencing technology to deliver extremely accurate results. Learn more about our two panels below.
Novelvi® Essential
Screens for the 3 most common aneuploidies:
- Trisomy 21 (Down syndrome)
- Intellectual disability, distinct facial features, and muscle weakness during infancy.
- Trisomy 18 (Edwards syndrome)
- Intrauterine growth retardation, small abnormally shaped head, and other birth defects.
- Trisomy 13 (Patau syndrome)
- Severe intellectual disability and a variety of physical defects affecting many organs.
Novelvi® Ultra
Screens all 24 chromosomes for aneuploidy plus clinically relevant microdeletions. These include:
- Trisomy 13, 18, and 21
- Sex chromosome aneuploidies
- Monosomy X (Turner syndrome)
- Trisomy X (Triple X syndrome)
- XXY (Klinefelter sydrome)
- XYY syndrome
- Microdeletions (upon request)
- 4p16.3 deletion (Wolf-Hirschhorn syndrome)
- 5p deletion (Cri-du-chat syndrome)
- 15q11.2 (Prader-Willi syndrome/ Angelman syndrome)
- 22q11.2 deletion (DiGeorge syndrome)